Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Ключови думи
Резюме
Описание
PRIMARY OBJECTIVES:
I. To evaluate the effect of clofarabine induction and consolidation therapy on overall survival in comparison with standard therapy (daunorubicin [daunorubicin hydrochloride] & cytarabine) in newly-diagnosed acute myeloid leukemia (AML) patients age >= 60 years.
SECONDARY OBJECTIVES:
I. To evaluate complete remission (CR) rates, duration of remission, and toxicity/treatment-related mortality of clofarabine in comparison with standard therapy (daunorubicin & cytarabine) in newly-diagnosed AML patients age >= 60 years.
II. To evaluate the feasibility of consolidation with reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation from human leukocyte antigen (HLA)-identical donors in patients who achieve a response to induction therapy, including the incidence of successful engraftment, acute and chronic graft-versus-host disease, transplant-related mortality, and its impact on overall survival in comparison to patients receiving chemotherapy.
III. To evaluate the duration of remission and disease-free survival of patients in complete remission following completion of consolidation therapy who are subsequently randomized to receive scheduled low-dose decitabine maintenance in comparison with observation.
IV. To perform expression and methylation profiling on all patients receiving decitabine and to correlate their integrated epigenetic signatures with response to decitabine.
V. To examine the epigenetic profiles of remission marrow in patients randomized to observation vs. decitabine to determine whether epigenetic signature of apparently morphologically normal bone marrow is predictive of relapse or response to decitabine maintenance.
VI. To explore the possible association of response to clofarabine with ABC-transporter P-glycoprotein (Pgp).
VII. To assess the intensity of expression of CXC chemokine receptor type 4 (CXCR4) on diagnostic leukemia cells and to correlate this parameter with other established prognostic factors.
VIII. To assess the entire spectrum of somatic mutations and affected pathways at diagnosis of AML and elucidate the association between gene mutation and outcome.
IX. To examine the impact of smoking, obesity, regular acetaminophen use, regular aspirin use, benzene exposure, living in a rural/farm environment and some other underlying exposures and lifestyle factors associated with AML development on overall survival (OS).
X. To investigate potential correlative results between array comparative genomic hybridization (CGH) findings and acute myeloid leukemia patient characteristics.
TERTIARY OBJECTIVES:
I. To compare health-related quality of life (QOL) (physical, functional, leukemia-specific well-being) and fatigue in elderly AML patients receiving standard induction therapy with those receiving clofarabine.
II. To measure the change in health-related QOL that occurs over time (within treatment groups).
III. To comprehensively assess patient function at the time of study enrollment.
IV. To determine if components of a comprehensive geriatric assessment or QOL scales predict ability to complete AML treatment.
V. To describe the impact of transplant on QOL in AML patients above age 60.
OUTLINE:
INDUCTION THERAPY: Patients are randomized to 1 of 2 treatment arms.
ARM I (STANDARD THERAPY): Patients receive daunorubicin hydrochloride intravenously (IV) over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients with residual disease or those who do not achieve an aplastic bone marrow on day 12-14 (i.e., < 5% blasts and < 20% cellularity or markedly/moderately hypocellular) may receive a second course of induction therapy beginning no sooner than day 14.
ARM II: Patients receive clofarabine IV over 1 hour on days 1-5. Patients with residual disease or those who do not achieve an aplastic bone marrow on day 12-14 (i.e., < 5% blasts and < 20% cellularity or markedly/moderately hypocellular) may receive a second course of induction therapy beginning no sooner than day 21 and no later than day 56.
Patients who achieve a complete remission (CR) or CR with incomplete marrow recovery (CRi) after induction therapy proceed to consolidation therapy. Patients who are 60-69 years of age who achieve a "morphologic leukemia-free state" after induction therapy and who have an HLA-identical donor proceed to allogeneic stem cell transplantation.
CONSOLIDATION THERAPY: Beginning within 60 days after documentation of CR or CRi, patients receive consolidation therapy in the same arm they were randomized to for induction therapy.
ARM I (STANDARD THERAPY): Patients receive cytarabine IV over 1 hour once or twice daily on days 1-6. Treatment repeats every 4-6 weeks for 2 courses.
ARM II: Patients receive clofarabine IV over 1 hour on days 1-5. Treatment repeats every 4-6 weeks for 2 courses.
Patients who remain in CR after completion of consolidation therapy proceed to maintenance therapy.
MAINTENANCE THERAPY: Beginning within 60 days after completion of consolidation therapy, patients receive maintenance therapy and are randomized to 1 of 2 arms. Patients not eligible for randomization to decitabine maintenance after recovery from consolidation will be followed according to Arm I.
ARM I: Patients undergo observation monthly for 12 months.
ARM II: Patients receive decitabine IV over 1 hour on days 1-3. Treatment repeats every 4 weeks for 12 months the absence of unacceptable toxicity.
ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING REGIMEN: Patients begin reduced-intensity conditioning 30-90 days after the initiation of induction therapy.
CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 2 hours every 6 hours on days -4 and -3 (for a total of 8 doses), and anti-thymocyte globulin IV over 4-6 hours on days -4 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
After completion of study treatment, patients are followed up every 3 months for 4 years, every 6 months for 1 year, and then annually thereafter.
Дати
| Последна проверка: | 11/30/2018 |
| Първо изпратено: | 03/10/2014 |
| Очаквано записване подадено: | 03/10/2014 |
| Първо публикувано: | 03/11/2014 |
| Изпратена последна актуализация: | 12/11/2018 |
| Последна актуализация публикувана: | 12/12/2018 |
| Действителна начална дата на проучването: | 12/27/2010 |
| Приблизителна дата на първично завършване: | 06/29/2019 |
Състояние или заболяване
Интервенция / лечение
Drug: Arm II (clofarabine)
Drug: Arm I (daunorubicin hydrochloride and cytarabine)
Other: Arm I (daunorubicin hydrochloride and cytarabine)
Drug: Arm I (daunorubicin hydrochloride and cytarabine)
Drug: Arm II (clofarabine)
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment
Other: questionnaire administration
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Active Comparator: Arm I (daunorubicin hydrochloride and cytarabine) See Detailed Description | Drug: Arm I (daunorubicin hydrochloride and cytarabine) Given IV |
| Experimental: Arm II (clofarabine) See Detailed Description | Drug: Arm II (clofarabine) Given IV |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 60 Years Да се 60 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Sexually active males must be strongly advised to use an accepted and effective method of contraception - Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1 - Total bilirubin =< grade 1 - Note: If total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible - Patient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS]) - Patient must not have an active, uncontrolled infection - ADDITIONAL INDUCTION ELIGIBILITY CRITERIA: - Newly-diagnosed AML patients according to World Health Organization (WHO) classification who are considered candidates for intensive chemotherapy based upon examination of peripheral blood or bone marrow aspirate specimens or touch preparations of the bone marrow biopsy obtained within two weeks prior to randomization; a bone marrow aspirate is required for enrollment; however, on occasion there is discordance between percentage of myeloblasts on the differential of the peripheral blood or aspirate; the peripheral blood criteria are sufficient for diagnosis; confirmatory immunophenotyping will be performed centrally - NOTE: patients must be registered to E3903 (Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for Eastern Cooperative Oncology Group (ECOG) Treatment Trials for Leukemia or Related Hematologic Disorders) and must undergo eligibility testing for the study by multiparameter flow cytometry - NOTE: Southwest Oncology Group (SWOG)/Cancer Trials Support Unit (CTSU) institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906 - ECOG performance status (PS) 0-3 (restricted to ECOG PS 0-2 if >= 70 years of age) - Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded - Patients must not have blastic transformation of chronic myelogenous leukemia - Patients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML - NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excluded - Patients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis - Total serum bilirubin =< 1.5 times upper limit of normal (ULN) (=< grade 1); if total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible - Patients with a serum creatinine > 1 are eligible if they have a calculated glomerular filtration rate (GFR) of >= 60 ml/min (i.e. class I or class II chronic kidney disease ) using the Modification of Diet in Renal Disease (MDRD) formula - Note: Daily creatinine and MDRD formula are only for the 1st induction cycle - Cardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment - NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment - Patients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excluded - Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if adequate number of circulating blasts (>10^9/l) from peripheral blood; this must be done via E3903 - NOTE: SWOG/CTSU institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906 - Patients who have received previous treatment for antecedent hematological disorders (AHD) with 5-azacitidine, decitabine, or low dose cytarabine will be excluded - Patients with known human immunodeficiency virus (HIV) infection are excluded - HLA typing should be performed at registration, if possible - Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing; this must be done via E2906 - NOTE: SWOG/CTSU institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906 - CONSOLIDATION CRITERIA: - NOTE: All patients achieving CR or complete remission with incomplete blood count recovery (CRi) will receive consolidation when fit - NOTE: Patients proceeding to transplant are allowed up to one cycle of consolidation treatment - Consolidation cycle 1 must commence within sixty days of the bone marrow aspirate and biopsy that confirmed the presence of a CR or CRi - Patients must have achieved a CR or CRi (or morphologic leukemia-free state for those patients proceeding to Arm G transplant) - Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi - Patients must have an ECOG performance status of 0-2 - Patients must have resolved any serious infectious complications related to induction - NOTE: Patients with an HLA-matched donor and proceeding to transplant will be allowed up to one cycle of consolidation treatment - Any significant medical complications related to induction must have resolved - Patients must have a creatinine and AST =< grade 1 - MAINTENANCE CRITERIA: - Maintenance should commence within 60 days of recovery of peripheral blood counts after consolidation cycle 2; patients must begin consolidation cycle 2 within 60 days of recovery to be eligible for further therapy - Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy and cytogenetic analysis - Patients must have an ECOG performance status of 0 -2 - Patients must have resolved any serious infectious complications related to consolidation cycle 2 - Any significant medical complications related to consolidation cycle 2 must have resolved - Total serum bilirubin =< 1.5 x ULN - NOTE: if total bilirubin is 2-3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible - Serum creatinine =< grade 1 - The absolute neutrophil count (ANC) must be > 1000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover - The platelet count must be > 75,000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover - ALLOGENEIC TRANSPLANTATION: - Patients must be > 30 days and < 90 days from the start of induction or re-induction chemotherapy, or > 30 days and < 90 days of recovery from consolidation cycle 1 (if received), and must have achieved a response to induction therapy (CR, CRi, or "morphologic disease-free state", documented > 27 days after start of most-recent chemotherapy) - Patients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatment - Patients must have a total serum bilirubin =< 1.5 x ULN (grade =< 1) and a serum creatinine =< grade 1 - An eligible HLA-identical donor (either related or unrelated) should be available; in sibling donors, low resolution HLA typing (A,B,DR) will be considered sufficient; in the case of unrelated donors, high-resolution class I and II typing (A, B, C, DRB1 and DQ) should be matched at all 10 loci; donors must be willing and able to undergo peripheral blood progenitor mobilization - HLA-identical sibling (6/6): the donor must be determined to be an HLA-identical sibling (6/6) by serologic typing for class (A, B) and low resolution molecular typing for class II (DRB1) - Matched unrelated donor (10/10): high resolution molecular typing at the following loci is required: HLA-A, -B, -C, -DRBL, and -DQB1 - NOTE: for matched donors - will allow select 1 antigen mismatched sibling donors and unrelated donors in accordance with site institutional standard, as long as matched at HLA-A, HLA-B, HLA-C, and DRB1, and with advanced discussion/approval by the Study Chair and the bone marrow transplant (BMT) co-chair - Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance - Patients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation - Diffusion capacity of carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease - No known hypersensitivity to Escherichia (E.) coli-derived products - No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies - Creatinine =< grade 1 - Bilirubin =< grade 1 - If bilirubin is 2-3 mg/dL, but direct bilirubin is normal then patient will be considered eligible - AST =< grade 1 |
Резултат
Първични изходни мерки
1. Overall survival [Time between randomization and death from any cause, assessed up to 5 years]
Вторични изходни мерки
1. Mortality rate [30 days]
2. Induction complete response rates [Up to 5 years]
3. Disease-free survival (DFS) [Time from the second randomization to relapse or death without relapse, assessed up to 5 years]
4. Overall survival [Up to 5 years]
5. Epidemiological factors, measured using the Acute Leukemia Epidemiology and Survival in ECOG (ALESE) questionnaire [Baseline]
6. Change in the Functional Assessment of Cancer Therapy (FACT)-Leukemia-specific (Leu) Trial Outcome Index (TOI) score [Baseline to 30 days after beginning induction therapy]
7. Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score [Baseline to 30 days after beginning induction therapy]
Други изходни мерки
1. Epigenetic signatures, determined by expression and methylation profiling [Up to 5 years]
2. Gene expression levels [Up to 5 years]
3. Predictive mutations [Up to 5 years]
4. Prognostic risk groups [Up to 5 years]
5. Pgp levels [Up to 5 years]
6. CXCR4 expression levels [Up to 5 years]
